Immunotherapy vs. chemo for MS anal cancer trial
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests sintilimab (a type of immunotherapy) against mitomycin plus chemotherapy with radiation for anal cancer that hasn't spread. It aims to find a better treatment with fewer side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have anal squamous cell carcinoma that has not spread to other organs.
- You have not had surgery, chemo, or other treatments for this cancer before.
- You are between 18 and 75 years old and active enough to do daily tasks.
- Your kidneys, liver, and blood counts are working well enough.
- You are not pregnant or breastfeeding, and agree to use birth control if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of brief radiation therapy followed by immunotherapy and chemotherapy for locally advanced rectal cancer that hasn't spread. The goal is to see if this approach helps patients avoid or reduce surgery while controlling their cancer.
This trial tests combining immunotherapy with standard chemotherapy and radiation before surgery for locally advanced rectal cancer. It aims to see if this approach can improve outcomes for patients whose tumors have certain genetic features (pMMR or MSS).
This Phase 2 trial studies a combination of immunotherapy (spartalizumab), chemotherapy (mDCF includes docetaxel), and radiation to treat metastatic or returning anal squamous cell cancer. It may help shrink tumors and improve outcomes compared with standard approaches, but eligibility is strict to keep participants safe.
This trial tests whether adding an immunotherapy drug (retifanlimab) to standard chemoradiation improves outcomes for people with locally advanced anal cancer. The treatment is adjusted based on HPV DNA levels in your blood.
This study tests a combination of chemotherapy, radiation therapy, and an immunotherapy drug (anti-PD-1 antibody) for anal squamous cell cancer. The trial enrolls patients at different stages of disease to see if adding immunotherapy improves outcomes.
This trial tests an adaptive, image-guided radiation plan for anal canal squamous-type cancers. It may help deliver effective treatment while adjusting the radiation based on how your body and tumor respond.
Hear when a new Anal Squamous Cell Carcinoma, Limited-stage trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.